Researchers have identified a key gene, SRRM1, that helps pancreatic cancer cells resist gemcitabine, the standard first-line chemotherapy. Higher levels of SRRM1 are linked to more advanced disease, metastasis, and poorer survival outcomes. When SRRM1 is blocked in resistant cancer cells, they become sensitive again to gemcitabine, suggesting it plays a central role in treatment failure.
The study shows that SRRM1 helps cancer cells avoid a form of cell death called ferroptosis, which depends on iron and lipid damage inside cells. It is activated through a pathway involving NRF2 and supports the activity of GPX4, a protein that protects tumor cells from oxidative damage. When SRRM1 is inhibited, cancer cells build up toxic iron and reactive molecules, leading to cell death.
In animal models, combining gemcitabine with a ferroptosis-inducing drug significantly reduced tumor growth compared to either treatment alone. Researchers say this combined approach could help overcome chemotherapy resistance and improve outcomes for patients with advanced pancreatic cancer.